Pharma: Clinic Roundup
Ferring Pharmaceuticals SA, of Saint Prex, Switzerland, presented data at the European Association of Urology 2013 annual meeting in Milan, Italy, showing that degarelix (Firmagon), a gonatropin-releasing hormone antagonist for prostate cancer, may be associated with a lower risk of a cardiovascular event or death compared to luteinizing hormone-releasing agonists.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter